- An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Fiedler, W., Mesters, R., Heuser, M., Ehninger, G., Berdel, W.E., Zirrgiebel, U., Robertson, J.D., Puchalski, T.A., Collins, B., Jürgensmeier, J.M., Serve, H. Leuk. Res. (2010)